Fortress Biotech, Inc.
FBIO
$2.76
$0.072.60%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.38% | 0.76% | 0.84% | -29.21% | -5.57% |
| Total Other Revenue | -- | -- | -- | -94.74% | -- |
| Total Revenue | 20.52% | 10.18% | 0.84% | -61.18% | -7.13% |
| Cost of Revenue | -57.15% | -28.99% | -71.70% | -25.40% | -48.03% |
| Gross Profit | 1,538.76% | 195.60% | 124.77% | -86.99% | 106.46% |
| SG&A Expenses | -20.82% | 86.13% | 43.04% | 41.93% | 1.20% |
| Depreciation & Amortization | 30.71% | 30.71% | 30.84% | -9.11% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.44% | 32.10% | -28.51% | -6.03% | -24.30% |
| Operating Income | 69.17% | -45.09% | 38.97% | -855.24% | 32.55% |
| Income Before Tax | 133.25% | 59.57% | 36.73% | 9.18% | -151.58% |
| Income Tax Expenses | -62.32% | -- | -- | -11.35% | -51.06% |
| Earnings from Continuing Operations | 133.07% | 59.57% | 36.73% | 9.21% | -148.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -121.53% | 51.82% | -40.24% | -0.79% | 143.48% |
| Net Income | 145.47% | 241.45% | 31.35% | 27.09% | -155.04% |
| EBIT | 69.17% | -45.09% | 38.97% | -855.24% | 32.55% |
| EBITDA | 73.25% | -47.47% | 40.28% | -583.07% | 33.04% |
| EPS Basic | 117.67% | 168.22% | 53.83% | 64.65% | 18.82% |
| Normalized Basic EPS | 1,605.48% | 30.43% | -9.63% | -86.05% | 98.29% |
| EPS Diluted | 114.41% | 161.64% | 53.83% | 64.65% | 18.82% |
| Normalized Diluted EPS | 1,339.38% | 17.51% | -9.63% | -86.05% | 98.29% |
| Average Basic Shares Outstanding | 38.32% | 46.75% | 54.21% | 141.96% | 162.68% |
| Average Diluted Shares Outstanding | 68.05% | 62.82% | 54.21% | 141.96% | 162.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | 1.00% | 1.00% |